OpenLB
Open Library of Bioscience
Advanced Search
Nature communications
06 30, 2021;12 (1): 4048.

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2.

Donata Hoffmann, Björn Corleis, Susanne Rauch, Nicole Roth, Janine Mühe, Nico Joel Halwe, Lorenz Ulrich, Charlie Fricke, Jacob Schön, Anna Kraft, Angele Breithaupt, Kerstin Wernike, Anna Michelitsch, Franziska Sick, Claudia Wylezich, Bernd Hoffmann, Moritz Thran, Andreas Thess, Stefan O Mueller, Thomas C Mettenleiter, Benjamin Petsch, Anca Dorhoi, Martin Beer
Author Information
  1. Donata Hoffmann: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. ORCID
  2. Björn Corleis: Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  3. Susanne Rauch: CureVac AG, Tübingen, Germany.
  4. Nicole Roth: CureVac AG, Tübingen, Germany.
  5. Janine Mühe: CureVac AG, Tübingen, Germany.
  6. Nico Joel Halwe: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. ORCID
  7. Lorenz Ulrich: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. ORCID
  8. Charlie Fricke: Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. ORCID
  9. Jacob Schön: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  10. Anna Kraft: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. ORCID
  11. Angele Breithaupt: Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. ORCID
  12. Kerstin Wernike: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. ORCID
  13. Anna Michelitsch: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. ORCID
  14. Franziska Sick: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  15. Claudia Wylezich: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. ORCID
  16. Bernd Hoffmann: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  17. Moritz Thran: CureVac AG, Tübingen, Germany.
  18. Andreas Thess: CureVac AG, Tübingen, Germany. ORCID
  19. Stefan O Mueller: CureVac AG, Tübingen, Germany.
  20. Thomas C Mettenleiter: Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany.
  21. Benjamin Petsch: CureVac AG, Tübingen, Germany.
  22. Anca Dorhoi: Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. anca.dorhoi@fli.de. ORCID
  23. Martin Beer: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. martin.beer@fli.de. ORCID
PMID: 34193869 DOI: 10.1038/s41467-021-24339-7

Abstract

The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls. mRNA-immunized mice develop elevated SARS-CoV-2 RBD-specific antibody and neutralization titers which are readily detectable, but significantly reduced against VOC B.1.351. The mRNA vaccines fully protect from disease and mortality caused by either viral strain. SARS-CoV-2 remains undetected in swabs, lung, or brain in these groups. Despite lower neutralizing antibody titers compared to the ancestral strain BavPat1, CVnCoV and CV2CoV show complete disease protection against the novel VOC B.1.351 in our studies.

References

  1. Nat Med. 2021 Apr;27(4):622-625 [PMID: 33654292]
  2. Nat Med. 2021 Apr;27(4):620-621 [PMID: 33558724]
  3. Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4 [PMID: 33535027]
  4. Nature. 2021 Feb;590(7847):630-634 [PMID: 33276369]
  5. Mol Phylogenet Evol. 2021 Apr;157:107017 [PMID: 33242581]
  6. Nat Rev Microbiol. 2021 Mar;19(3):141-154 [PMID: 33024307]
  7. Nature. 2020 Oct;586(7830):516-527 [PMID: 32967006]
  8. Nat Med. 2021 Mar;27(3):440-446 [PMID: 33531709]
  9. Signal Transduct Target Ther. 2020 Oct 13;5(1):237 [PMID: 33051445]
  10. Cell Rep Med. 2021 Feb 16;2(2):100204 [PMID: 33521695]
  11. Nature. 2021 May;593(7857):136-141 [PMID: 33706364]
  12. Nat Immunol. 2020 Nov;21(11):1327-1335 [PMID: 32839612]
  13. Cell. 2021 Apr 29;184(9):2372-2383.e9 [PMID: 33743213]
  14. Sci Immunol. 2021 Mar 4;6(57): [PMID: 33664060]
  15. Nature. 2021 May;593(7857):142-146 [PMID: 33780970]
  16. Nature. 2020 Oct;586(7830):509-515 [PMID: 32967005]
  17. Cell. 2021 Jan 21;184(2):476-488.e11 [PMID: 33412089]
  18. Sci Transl Med. 2021 Jan 27;13(578): [PMID: 33431511]
  19. Transbound Emerg Dis. 2020 Nov 15;: [PMID: 33191578]
  20. Cell. 2020 Aug 20;182(4):812-827.e19 [PMID: 32697968]
  21. Science. 2021 Mar 12;371(6534):1152-1153 [PMID: 33514629]
  22. Nat Commun. 2020 Nov 30;11(1):6122 [PMID: 33257679]
  23. Nature. 2021 Apr;592(7852):122-127 [PMID: 33636719]
  24. Nat Commun. 2020 Nov 27;11(1):6059 [PMID: 33247099]
  25. NPJ Vaccines. 2021 Apr 16;6(1):57 [PMID: 33863911]
  26. Lancet. 2021 Feb 6;397(10273):452-455 [PMID: 33515491]
  27. Cell. 2021 Apr 29;184(9):2348-2361.e6 [PMID: 33730597]
  28. Sci Rep. 2018 Aug 30;8(1):13108 [PMID: 30166611]
  29. EBioMedicine. 2021 Jun;68:103403 [PMID: 34049240]
  30. N Engl J Med. 2021 Mar 17;384(15):1468-1470 [PMID: 33730471]
  31. N Engl J Med. 2021 May 20;384(20):1885-1898 [PMID: 33725432]
  32. Science. 2020 Dec 18;370(6523):1464-1468 [PMID: 33184236]

Grants

  1. 01KI20703/Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)

MeSH Term

Angiotensin-Converting Enzyme 2
Animals
Antibodies, Neutralizing
Antibodies, Viral
COVID-19
COVID-19 Vaccines
Cell Line
Chlorocebus aethiops
Genome, Viral
Humans
Mice
Mice, Transgenic
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Vero Cells

Chemicals

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
ACE2 protein, human
Angiotensin-Converting Enzyme 2
Journal Article Research Support, Non-U.S. Gov't
Article has an altmetric score of 28

Word Cloud

Similar Articles

Cited By